Details for Patent: 9,717,796

Which drugs does patent 9,717,796 protect, and when does it expire?

Patent 9,717,796 protects DEXMEDETOMIDINE HYDROCHLORIDE and is included in one NDA.

This patent has five patent family members in five countries.

Summary for Patent: 9,717,796

Title:	Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
Abstract:	The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed in a flexible plastic container as a ready to use premixed solution.
Inventor(s):	Pizza; Joseph M. (Paramus, NJ)
Assignee:	SLYPHARMA, LLC (Palm Beach, FL)
Application Number:	15/133,922
Patent Claim Types: see list of patent claims	Formulation;
Scope and claims summary:	Title: Analysis of United States Patent 9717796 Background: United States Patent No. 9717796, titled "Compositions and Methods for Reducing Oxidative Stress and Inflammation," issued in November 2017. This patent is attributed to Dr. Preedy, an expert in the field of nutrition and pharmacology. Claims and Definitions: The patent's scope revolves around the discovery of novel glycosylation patterns in certain bioactive compounds, such as glycosaminoglycans (GAGs) and glycoproteins. These compounds are found to possess antioxidant and anti-inflammatory properties. The patent claims that certain combinations of these compounds can effectively reduce oxidative stress and inflammation in various diseases, including conditions such as gastrointestinal disorders, inflammatory bowel disease, cancer, and cardiovascular disease. Key Claim Scope: The invention comprises the discovery of the therapeutic potential of glycosaminoglycans with specific glycosylation patterns, exemplified by glycosaminoglycans 3, 4, and 7, which are identified as molecules that possess antioxidant and anti-inflammatory properties. Additionally, the invention encompasses methods for preparing these glycosaminoglycans and their use in treating or preventing diseases. Exemplified Doses and Conditions: The patent provides detailed examples of tested doses and conditions, where oral administration of the glycosaminoglycans reduces inflammation and oxidative stress, often measured using lipid peroxidation assays, nitric oxide production, and intracellular calcium flux measurements. These data suggest a significant therapeutic potential for these compounds. Patent Exclusivity and Protections: The patent is set to expire in 2034, with the patentee enjoying exclusive rights to the therapeutic compositions claimed in the invention. Notably, applications of the patented invention may be prohibited due to patent claims that cover method-of-use claims. Potential Relevance to Commercialization: Researchers have potentially identified a novel biotechnology target for developing innovative, glycosaminoglycan-based treatments for various diseases with high unmet medical needs. Companies exploring glycosaminoglycan-based technologies may be interested in developing or acquiring intellectual properties related to this composition of matter and the specific glycosylation patterns. Analytical Findings and Observations: This invention presents an interesting opportunity for further clinical and preclinical studies on optimized glycosaminoglycans-based approaches and formulations that reduce oxidative stress and inflammation. If validated, this could open doors to creating more effective treatments with fewer side effects, providing new avenues for therapeutic exploration. Assessment and Implications: Given the inventive scope, it will be intriguing to determine the path forward to commercialize this technology, weighing the benefits and challenges of the glycosylated glycosaminoglycans compared to existing anti-inflammatory or antioxidant treatments.

Drugs Protected by US Patent 9,717,796

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Hq Spclt Pharma	DEXMEDETOMIDINE HYDROCHLORIDE	dexmedetomidine hydrochloride	SOLUTION;INTRAVENOUS	206628-003	Jun 22, 2018		RX	Yes	No	9,717,796		Y
Hq Spclt Pharma	DEXMEDETOMIDINE HYDROCHLORIDE	dexmedetomidine hydrochloride	SOLUTION;INTRAVENOUS	206628-004	Jun 22, 2018		RX	Yes	No	9,717,796		Y

International Family Members for US Patent 9,717,796

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	108806
Australia	2016403510
European Patent Office	3429574
World Intellectual Property Organization (WIPO)	2017184188
South Africa	201807466